Lymphoma Immunotherapy: Monoclonal Antibodies and Mechanism of Action, Antibody-Drug Conjugates, Immune Checkpoint Inhibitors, Immune-related Adverse Effects, Allogeneic HTC, T-cell Immunotherapy
By
2018 Pan Pacific Lymphoma Conference
FEATURING
Laura Zitella
By
2018 Pan Pacific Lymphoma Conference
FEATURING
Laura Zitella
Comments 0
Login to view comments.
Click here to Login